{"task_id": "aa4602403d795eb8", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 331/464)", "text": " change\nImproved\nNo change\nParkinson\u2019s Disease\n321\n\n--- Page 343 ---\nCLINICAL FEATURES (CONT\u2019D)\nCHARACTERIZING MOVEMENT DISORDERS\n\u0002\nSPEED\nslow (dystonia, athetosis, dystonic tics),\nmoderate (chorea, tremor, asterixis), quick (myo\nclonus, myoclonic tics)\n\u0002\nSUPPRESSIBILITY\nvolitional in tics, sensory tricks in\ndystonia, activity in rest tremor\n\u0002\nAGGRAVATING FACTORS\nstress, anxiety. Improves\nwith rest and sleep\n\u0002\nPRECIPITATING FACTORS\nalcohol, caffeine, stress,\nfatigue,\ncold,\nquick\nmovements,\nprolonged\nexercises\nINVESTIGATIONS\nSPECIAL\n\u0002\nIMAGING\nCT/MR head, particularly if atypical\nfeatures\nINVESTIGATIONS FOR HYPERKINETIC MOVEMENT\nDISORDERS\nBASIC\n\u0002\nLABS\nCBCD, lytes, urea, Cr, glucose, AST, ALT,\nALP, bilirubin, LDH, CK, INR, PTT, urinalysis\n\u0002\nIMAGING\nCT head, MRI head\nSPECIAL\n\u0002\nFURTHER NEUROLOGIC WORKUP\nEMG/NCS, mus\ncle/nerve biopsy, lumbar puncture, genetic test\ning (CAG repeats), and smear for acanthocytes if\nsuspect Huntington\u2019s disease\n\u0002\nINFLAMMATORY WORKUP\nESR, CRP, ANA, ENA, RF,\nANCA, C3, C4, lupus anticoagulant, antiphospho\nlipid antibody, antistreptolysin O\n\u0002\nMALIGNANCY WORKUP\nquantitative immunoglo\nbulin, serum protein electrophoresis\n\u0002\nENDOCRINE WORKUP\nTSH, PTH\n\u0002\nMETABOLIC WORKUP\ncopper, 24 h urinary cop\nper, vitamin B12, ceruloplasmin, RBC folate, lac\ntate pyruvate\nMANAGEMENT\nTREAT UNDERLYING CAUSE\n\u0002\nSINEMET\ncarbidopa/levodopa 25/100 25/250 mg\nPO TID. Combined use with entacapone can lead to\nmore sustained levodopa levels. See NEJM 2008\n359:23 for details\n\u0002\nDOPAMINE AGONISTS\nbromocriptine 5 10 mg PO\nBID, pramipexole, ropinirole, pergolide. Ineffective\nin patients unresponsive to levodopa\nMANAGEMENT (CONT\u2019D)\n\u0002 COMT\nand\nMAO B\ninhibitors\nentacapone\n200 mg with each dose of levodopa, rasagiline\n0.5 1 mg PO daily\n\u0002\nANTICHOLINERGICS\nbenztropine 0.5 2 mg PO BID\n\u0002\nAMANTADINE\namantadine 200 300 mg PO daily\n\u0002\nAPPROACH\nSinemet should be first line therapy\nfor most patients because of its effectiveness.\nCOMT/MAO B inhibitors or dopamine agonists\nmay be used in combination with Sinemet or as\nfirst line agent alone for young patients. Anticho\nlinergics have limited activity but can help with\ntremor and dyskinesia. Amantadine may be useful\nfor mild disease and dyskinesia\n\u0002\nDYSKINESIA\na classic complication of Sinemet.\nConsider lowering dose of levodopa, changing\nits timing/frequency, and replacing part of\nthe levodopa dose with a dopamine agonist.\nAmantadine\nmay\nbe\nadded\nto\ncounteract\ndyskinesia\nSYMPTOM MANAGEMENT\n\u0002\nGENERAL\neducation, support, exercise, speech\ntherapy\n\u0002\nNAUSEA\ndomperidone is safe as it does not cross\nthe blood brain barrier. Avoid antidopaminergic\nmedications such as metoclopramide and phe\nnothiazines (prochlorperazine, chlorpromazine)\n\u0002\nPSYCHOSIS AND HALLUCINATIONS\nconsider stopping\nanti Parkinsonian drugs in sequence. May need to\nstart atypical neuroleptic antipsychotics such as\nquetiapine or clozapine. Avoid older neuroleptic\nantipsychotics such as haloperidol\n\u0002\nDEPRESSION\nantidepressants such as TCAs and\nSSRIs may be used with caution\nSPECIFIC ENTITIES\nGAIT ASSESSMENT\n\u0002\nGENERAL INSPECTION\ninspect pelvis, knees, ankles,\nand feet for asymmetry, deformity. Ask the patient\nto walk normally, then heel to toe, walk on heels,\nwalk on toes, and squat\n\u0002\nFOOT\nMOVEMENTS\nheel strike, foot flat (mid\nstance), heel off (lift off), toes off (swing)\n\u0002\nGAIT\nMOVEMENTS\ncomment\non\npace\nlength,\nwidth, coordination, and stability (see table\nbelow for specific pathologies)\n\u0002\nNEUROLOGICAL\nEXAMINATION\nlower limb motor\nand sensory examination. Also include Romberg\ntest\nType\nPathology\nSpastic gait\nUpper motor neuron lesion (stroke)\nScissor gait\nBilateral upper motor neuron disease\nApraxic/magnetic gait\nFrontal lobe (NPH, stroke)\n322\nParkinson\u2019s Disease", "text_length": 3704, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 331/464)", "type": "chunk", "chunk_index": 330, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.701961", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.702851", "status": "complete", "chunks_added": 2}